Chinese Japanese Germany Korea

(9α,13α)-5,6,8,14-Tetradehydro-2-hydroxy-3,6-dimethoxy-17-methylmorphinan-7-one

(9α,13α)-5,6,8,14-Tetradehydro-2-hydroxy-3,6-dimethoxy-17-methylmorphinan-7-one Structure
(9α,13α)-5,6,8,14-Tetradehydro-2-hydroxy-3,6-dimethoxy-17-methylmorphinan-7-one structure
CAS No.
25650-75-3
Chemical Name:
(9α,13α)-5,6,8,14-Tetradehydro-2-hydroxy-3,6-dimethoxy-17-methylmorphinan-7-one
Synonyms
Pallidine【Corydalis】;(9α,13α)-5,6,8,14-Tetradehydro-2-hydroxy-3,6-dimethoxy-17-methylmorphinan-7-one;Morphinan-7-one, 5,6,8,14-tetradehydro-2-hydroxy-3,6-dimethoxy-17-methyl-, (9α,13α)-
CBNumber:
CB62154110
Molecular Formula:
C19H21NO4
Molecular Weight:
327.38
MDL Number:
MOL File:
25650-75-3.mol
Request For Quotation

(9α,13α)-5,6,8,14-Tetradehydro-2-hydroxy-3,6-dimethoxy-17-methylmorphinan-7-one Properties

Boiling point 545.6±50.0 °C(Predicted)
Density 1.33±0.1 g/cm3(Predicted)
pka 9.47±0.40(Predicted)

(9α,13α)-5,6,8,14-Tetradehydro-2-hydroxy-3,6-dimethoxy-17-methylmorphinan-7-one Preparation Products And Raw materials

Raw materials

Preparation Products

(9α,13α)-5,6,8,14-Tetradehydro-2-hydroxy-3,6-dimethoxy-17-methylmorphinan-7-one Suppliers

Global( 1)Suppliers
Supplier Tel Email Country ProdList Advantage
Chengdu DeSiTe Biological Technology Co., Ltd 17308096051 3001048290@qq.com China 6219 58
Supplier Advantage
Chengdu DeSiTe Biological Technology Co., Ltd 58
(9α,13α)-5,6,8,14-Tetradehydro-2-hydroxy-3,6-dimethoxy-17-methylmorphinan-7-one Pallidine【Corydalis】 Morphinan-7-one, 5,6,8,14-tetradehydro-2-hydroxy-3,6-dimethoxy-17-methyl-, (9α,13α)- 25650-75-3
This site uses cookies
This website uses cookies and similar technologies to store and retrieve information about your use of this website. This information helps us to provide, analyse and improve our services, which may include personalised content or advertising. We may share this information with Google and other third parties. This cookies are necessary for our website to work properly . By clicking "Continue" or continuing to browse our site you are agreeing to our and our partners use of cookies.
Accept